• No image available for this medication
    • PROVIDE GOLD REGULAR

    • QTY 30
    • 15G-101/30
    • Liquid
    • Near  77381

PROVIDE GOLD REGULAR Lifestyle Interactions

  • Ergotamine Tartrate 2mg, Sublingual tablet

    Interaction: Tobacco
    Severity: Major
    Notes for Consumers: Do not smoke or use tobacco products while taking this medication. Smoking while taking this medication increases the risk for serious side effects. Contact your care team if you experience new or worsening side effects.
    Notes for Professionals: Advise patients to avoid smoking tobacco while taking ergot alkaloids. Concurrent use of vasoconstrictors, such as nicotine, with ergot alkaloids may result in enhanced vasoconstriction. Nicotine acts indirectly as a sympathomimetic agent by releasing catecholamines, potentially resulting in effects such as hypertension, coronary spasm, coronary ischemia, or cardiac arrhythmias, which may be additive with ergot alkaloids.
  • Ergotamine Tartrate 2mg, Sublingual tablet

    Interaction: Grapefruit juice
    Severity: Major
    Notes for Consumers: Taking grapefruit juice with Ergotamine might increase the risk of nausea, nervousness, chest pain, high blood pressure, palpitations, or other serious side effects, like pain, numbness or reduced circulation to the hands, feet or legs. Talk to your doctor about drinking grapefruit juice while taking Ergotamine.
    Notes for Professionals: The risk of ergot toxicity (e.g., vasospasm leading to cerebral ischemia, peripheral ischemia and/or other serious effects) from ergotamine is potentially increased by the use of CYP3A4 inhibitors. Grapefruit juice contains furanocoumarins that are metabolized by CYP3A4 to reactive intermediates. These intermediates form a covalent bond to the active site of the CYP3A4 enzyme, causing irreversible inactivation (mechanism-based inhibition). Consequently, CYP3A4 activity in the gut wall is inhibited until de novo synthesis returns the enzyme to its previous level. Therefore grapefruit juice may decrease ergotamine metabolism via CYP3A4. According to the manufacturers, the prescriber should consider the effects of other agents on CYP3A4 before concomitant use with ergotamine.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.